牛牛AI助理已提取核心訊息
On January 8, 2024, Johnson & Johnson announced its definitive agreement to acquire Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company, for approximately $2.0 billion in an all-cash transaction. The acquisition aims to strengthen Johnson & Johnson's oncology portfolio with Ambrx's advanced antibody drug conjugates (ADCs) and proprietary technology platform. Ambrx's lead product candidate, ARX517, targets metastatic castration-resistant prostate cancer, and the company also has other candidates in development for various cancer types. The transaction, which is expected to close in the first half of 2024, is subject to Ambrx shareholder approval and regulatory clearances. Upon completion, Ambrx will no longer be listed on the NASDAQ Global Select Market. This move reflects Johnson & Johnson's commitment to oncology innovation and the development of targeted therapeutics.
On January 8, 2024, Johnson & Johnson announced its definitive agreement to acquire Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company, for approximately $2.0 billion in an all-cash transaction. The acquisition aims to strengthen Johnson & Johnson's oncology portfolio with Ambrx's advanced antibody drug conjugates (ADCs) and proprietary technology platform. Ambrx's lead product candidate, ARX517, targets metastatic castration-resistant prostate cancer, and the company also has other candidates in development for various cancer types. The transaction, which is expected to close in the first half of 2024, is subject to Ambrx shareholder approval and regulatory clearances. Upon completion, Ambrx will no longer be listed on the NASDAQ Global Select Market. This move reflects Johnson & Johnson's commitment to oncology innovation and the development of targeted therapeutics.
2024年1月8日，強生公司宣佈以約20億美元的全現金交易收購臨床階段生物製藥公司Ambrx Biopharma, Inc. 的最終協議。此次收購旨在通過Ambrx的先進抗體藥物偶聯物（ADC）和專有技術平台加強強生公司的腫瘤產品組合。Ambrx的主要候選產品 ARX517 針對轉移性去勢抗性前列腺癌，該公司還針對各種癌症類型開發了其他候選產品。該交易預計將於2024年上半年完成，尚待Ambrx股東批准和監管許可。完成後，Ambrx將不再在納斯達克全球精選市場上市。此舉反映了強生對腫瘤學創新和靶向療法開發的承諾。
2024年1月8日，強生公司宣佈以約20億美元的全現金交易收購臨床階段生物製藥公司Ambrx Biopharma, Inc. 的最終協議。此次收購旨在通過Ambrx的先進抗體藥物偶聯物（ADC）和專有技術平台加強強生公司的腫瘤產品組合。Ambrx的主要候選產品 ARX517 針對轉移性去勢抗性前列腺癌，該公司還針對各種癌症類型開發了其他候選產品。該交易預計將於2024年上半年完成，尚待Ambrx股東批准和監管許可。完成後，Ambrx將不再在納斯達克全球精選市場上市。此舉反映了強生對腫瘤學創新和靶向療法開發的承諾。
有用
沒用